Tetraphase raises $15M for antibiotic work

Massachusetts-based Tetraphase Pharmaceuticals has closed the second tranche of its $25 million Series A financing. The $15 million tranche was funded by existing investors, including Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures. Tetraphase will use the funding to support the advancement of several antibiotic drug candidates.

"Since our inception, we have made significant progress, applying our unique technology to the development of several novel and potent antibiotic drug candidates," said Guy Macdonald, President and CEO. "We are very pleased that our investors share our enthusiasm for and confidence in our programs."

- take a look at TetraPhase's release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.